Back to discover
Drug

Carbidopa

Approved · FDA
ClassDOPA decarboxylase inhibitorEmerging researchLate-stage development
Also known as (S)-(-)-carbidopa, (S)-carbidopa, Alpha-methyldopa hydrazine, Atamet+15 more

(S)-(-)-carbidopa, (S)-carbidopa, Alpha-methyldopa hydrazine, Atamet, CARBIDOPA HYDRATE, Carbidopa-Levodopa, Crexont, Dhivy, Duopa, Lodosyn, Parcopa, Rytary, Sinemet, Stalevo, Vyalev, (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate, Carbidopa/Entacapone/Levodopa, Carbidopum, L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid.

RxNorm2019ChEMBLCHEMBL1200748UNIIMNX7R8C5VO
1
Research papers
2
Active clinical trials
DDC
Primary target
3
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effects of the Serotonin Precursor, 5-hydroxytryptophan, in the Injured Human Spinal Cord

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Label change: CARBIDOPA AND LEVODOPA (NDA217186)

Regulatory2026-05-15FDA

The Role of Dopamine in the Central Neural Signature of Chronic Pain

Clinical trial2026-05-15Results expected Q4 2027 · ClinicalTrials.gov

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Clinical trial2026-04-14Results posted · ClinicalTrials.gov

Label change: CARBIDOPA AND LEVODOPA (NDA217186)

Regulatory2026-03-19FDA

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Clinical trial2025-06-17Results posted · ClinicalTrials.gov

Clinical Study to Compare the Possible Safety and Efficacy of Pentoxifylline and Celecoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

Clinical trial2024-09-20Completed · ClinicalTrials.gov

Approval: CARBIDOPA AND LEVODOPA (NDA217186)

Regulatory2024-08-07FDA

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Clinical trial2024-04-04Results posted · ClinicalTrials.gov

The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals With Spinal Cord Injury

Clinical trial2023-12-30Suspended · ClinicalTrials.gov

A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects

Clinical trial2023-12-05Completed · ClinicalTrials.gov

Levodopa and the progression of Parkinson's disease.

Research2004-12-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Carbidopa
Aliases & brands
(S)-(-)-carbidopa(S)-carbidopaAlpha-methyldopa hydrazineAtametCARBIDOPA HYDRATECarbidopa-LevodopaCrexontDhivyDuopaLodosynParcopaRytarySinemetStalevoVyalev(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrateCarbidopa/Entacapone/LevodopaCarbidopumL-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
RxNorm CUI
2019
ChEMBL ID
CHEMBL1200748
UNII
MNX7R8C5VO
Primary mechanism
DOPA decarboxylase inhibitor
Regulatory jurisdictions
fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Aromatic-L-amino-acid decarboxylase
DDC · P20711
INHIBITORDOPA decarboxylase inhibitor

Regulatory timeline

3 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2024-08-07
Latest approval
2024-08-07
Authorities
FDA
Total events
3
fdaU.S. Food and Drug Administration· 3 events
2026-05-15Label change
Label change: CARBIDOPA AND LEVODOPA (NDA217186)
Evidence ↗
2026-03-19Label change
Label change: CARBIDOPA AND LEVODOPA (NDA217186)
Evidence ↗
2024-08-07Approval
Approval: CARBIDOPA AND LEVODOPA (NDA217186)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

33 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
33
registered trials across all phases
LATEST COMPLETION 2025
2
Active studies
2
Recruiting
10
Late-stage (III+)
27
Completed
4
Discontinued
PHASE DISTRIBUTIONn = 33
Phase 19Phase 1 / 25Phase 29Phase 2 / 33Phase 33Phase 42Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

CompletedPH IVVanderbilt University Medical Centern=152018

Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial

CompletedPH IVBaylor College of Medicinen=202008

Effects of the Serotonin Precursor, 5-hydroxytryptophan, in the Injured Human Spinal Cord

RecruitingPH II/IIIUniversity of Albertan=302026

The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals With Spinal Cord Injury

SuspendedPH II/IIIJessica M D'Amicon=302023

Kidney Dopamine Effects on Urinary Sodium Excretion in Postural Tachycardia Syndrome

CompletedPH II/IIIVanderbilt Universityn=322021

Recent completions

Trials that read out recently, adding to the completed evidence base.

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

CompletedPH I/IIUniversity of Michigann=52025

Clinical Study to Compare the Possible Safety and Efficacy of Pentoxifylline and Celecoxib in Patients With Parkinson's Disease Treated With Conventional Treatment

CompletedPH IIMostafa Bahaan=802024

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

CompletedPH I/IIUniversity of Michigann=132024

A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects

CompletedPH IImpax Laboratories, LLCn=352023

Sinemet in ALS and PLS

CompletedPH IWashington University School of Medicinen=152022

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

CompletedPH I/IIUniversity of Michigann=142022

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Levodopa and the progression of Parkinson's disease.

The New England journal of medicine · 2004 · 1,175 cites
Recent papers

Levodopa and the progression of Parkinson's disease.

The New England journal of medicine · 2004 · 1,175 cites
Journals, researchers & institutions
Top journals
  • The New England journal of medicine1
Leading researchers
  • Fahn S1
  • Kieburtz K1
  • Lang A1
  • Marek K1
  • Oakes D1
  • Olanow CW1
  • Rudolph A1
  • Shoulson I1
Leading institutions
free-text, unnormalised
  • Columbia University1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Levodopa

Studied across the same disease area as Carbidopa in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.